VIR Vir Biotechnology, Inc.
FY2025 10-K
Vir Biotechnology, Inc. (VIR) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model focused on development and commercialization of infectious disease therapeutics
- • New clinical programs highlighted: Phase 1 study of VIR-5525 and CHD ECLIPSE registrational program initiated with $125.5M milestone payments in 2025
Management Discussion & Analysis
- • Revenue $114.8M for FY 2025, down from $129.4M in FY 2024, a 11.3% decrease
- • Operating loss $354.7M in FY 2025 vs loss $348.0M in FY 2024, operating margin negative, slight deterioration
Risk Factors
- • Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate
- • Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.